GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sumitomo Pharma Co Ltd (STU:DPM) » Definitions » Inventory Turnover

Sumitomo Pharma Co (STU:DPM) Inventory Turnover : 0.35 (As of Sep. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Sumitomo Pharma Co Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Sumitomo Pharma Co's Cost of Goods Sold for the three months ended in Sep. 2024 was €236 Mil. Sumitomo Pharma Co's Average Total Inventories for the quarter that ended in Sep. 2024 was €666 Mil. Sumitomo Pharma Co's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.35.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Sumitomo Pharma Co's Days Inventory for the three months ended in Sep. 2024 was 257.89.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Sumitomo Pharma Co's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 1.17.


Sumitomo Pharma Co Inventory Turnover Historical Data

The historical data trend for Sumitomo Pharma Co's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sumitomo Pharma Co Inventory Turnover Chart

Sumitomo Pharma Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.82 1.54 1.64 1.76 1.14

Sumitomo Pharma Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.31 0.30 0.29 0.35

Sumitomo Pharma Co Inventory Turnover Calculation

Sumitomo Pharma Co's Inventory Turnover for the fiscal year that ended in Mar. 2024 is calculated as

Inventory Turnover (A: Mar. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Mar. 2024 ) / ((Total Inventories (A: Mar. 2023 ) + Total Inventories (A: Mar. 2024 )) / count )
=777.279 / ((659.67 + 708.337) / 2 )
=777.279 / 684.0035
=1.14

Sumitomo Pharma Co's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover (Q: Sep. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Sep. 2024 ) / ((Total Inventories (Q: Jun. 2024 ) + Total Inventories (Q: Sep. 2024 )) / count )
=235.584 / ((0 + 665.801) / 1 )
=235.584 / 665.801
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sumitomo Pharma Co  (STU:DPM) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Sumitomo Pharma Co's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Sep. 2024 )/Cost of Goods Sold (Q: Sep. 2024 )*Days in Period
=665.801/235.584*365 / 4
=257.89

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Sumitomo Pharma Co's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=665.801 / 567.712
=1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Sumitomo Pharma Co Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Sumitomo Pharma Co's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Sumitomo Pharma Co Business Description

Traded in Other Exchanges
Address
6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Sumitomo Pharma Co Headlines